J Gynecol Oncol.  2014 Apr;25(2):79-80. 10.3802/jgo.2014.25.2.79.

Surgery or chemoradiation for stage IB cervical cancer? How cost effectiveness impacts a complex decision

• Cohn DE

• KMID: 1708328
• DOI: http://doi.org/10.3802/jgo.2014.25.2.79

Abstract

No abstract available.

MeSH Terms

Cost-Benefit Analysis*
Uterine Cervical Neoplasms*

Reference

1. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997; 350:535–540.

2. Katanyoo K, Praditsitthikorn N, Tangjitgamol S, Manusirivithaya S, Supawattanabodee B. Cost-utility analysis of treatments for stage IB cervical cancer. J Gynecol Oncol. 2014; 25:97–104.

3. Dueñas-González A, Zarba JJ, Patel F, Alcedo JC, Beslija S, Casanova L, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011; 29:1678–1685.

4. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and metaanalysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008; 26:5802–5812.